A Phase I/II, First-In-Human, Open-Label, Dose-Escalation Study Of Tak-186, An Egfr  Cd3 Cobra T Cell Engager, In Adult Patients With Unresectable, Locally Advanced, Or Metastatic Solid Tumors
TAK-186
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase I/II, First-In-Human, Open-Label, Dose-Escalation Study Of Tak-186, An Egfr  Cd3 Cobra T Cell Engager, In Adult Patients With Unresectable, Locally Advanced, Or Metastatic Solid Tumors ### Output: TAK-186